دورية أكاديمية
Copaiba oil minimizes inflammation and promotes parenchyma re-epithelization in acute allergic asthma model induced by ovalbumin in BALB/c mice.
العنوان: | Copaiba oil minimizes inflammation and promotes parenchyma re-epithelization in acute allergic asthma model induced by ovalbumin in BALB/c mice. |
---|---|
المؤلفون: | Caputo LS; Department of Pharmaceutical Sciences, Federal University of Juiz de Fora, Juiz de Fora, Brazil., Alves CL; Department of Pharmaceutical Sciences, Federal University of Juiz de Fora, Juiz de Fora, Brazil., Laranjeira IM; Life and Health Sciences Research Institute, ICVS, School of Medicine, Campus of Gualtar, University of Minho, Braga, Portugal.; ICVS/3B‟s - PT Government Associate Laboratory, Braga, Portugal.; Centre for the Research and Technology of Agro-Environmental and Biological Sciences, CITAB, University of Trás-os-Montes e Alto Douro, Vila Real, Portugal.; Centre of Molecular and Environmental Biology, CBMA, University of Minho, Campus de Gualtar, Braga, Portugal., Fonseca-Rodrigues D; Life and Health Sciences Research Institute, ICVS, School of Medicine, Campus of Gualtar, University of Minho, Braga, Portugal.; ICVS/3B‟s - PT Government Associate Laboratory, Braga, Portugal., da Silva Filho AA; Department of Pharmaceutical Sciences, Federal University of Juiz de Fora, Juiz de Fora, Brazil., Dias ACP; Centre of Molecular and Environmental Biology, CBMA, University of Minho, Campus de Gualtar, Braga, Portugal., Pinto-Ribeiro F; Life and Health Sciences Research Institute, ICVS, School of Medicine, Campus of Gualtar, University of Minho, Braga, Portugal.; ICVS/3B‟s - PT Government Associate Laboratory, Braga, Portugal., Pereira Junior ODS; Department of Pharmaceutical Sciences, Federal University of Juiz de Fora, Juiz de Fora, Brazil., de Paula ACC; Department of Pharmaceutical Sciences, Federal University of Juiz de Fora, Juiz de Fora, Brazil., Nagato AC; Department of Physiology, Federal University of Juiz de Fora, UFJF, Juiz de Fora, Brazil., Corrêa JODA; Department of Pharmaceutical Sciences, Federal University of Juiz de Fora, Juiz de Fora, Brazil. |
المصدر: | Frontiers in pharmacology [Front Pharmacol] 2024 Apr 11; Vol. 15, pp. 1356598. Date of Electronic Publication: 2024 Apr 11 (Print Publication: 2024). |
نوع المنشور: | Journal Article |
اللغة: | English |
بيانات الدورية: | Publisher: Frontiers Media] Country of Publication: Switzerland NLM ID: 101548923 Publication Model: eCollection Cited Medium: Print ISSN: 1663-9812 (Print) Linking ISSN: 16639812 NLM ISO Abbreviation: Front Pharmacol Subsets: PubMed not MEDLINE |
أسماء مطبوعة: | Original Publication: [Lausanne : Frontiers Media] |
مستخلص: | Introduction: Asthma is a condition of airflow limitation, common throughout the world, with high mortality rates, especially as it still faces some obstacles in its management. As it constitutes a public health challenge, this study aimed to investigate the effect of copaiba oil (e.g., Copaifera langsdorffii ), as a treatment resource, at doses of 50 and 100 mg/kg on certain mediators of acute lung inflammation (IL-33, GATA3, FOXP3, STAT3, and TBET) and early mechanisms of lung remodeling (degradation of elastic fiber tissues, collagen deposition, and goblet cell hyperplasia). Methods: Using an ovalbumin-induced acute allergic asthma model in BALB/c mice, we analyzed the inflammatory mediators through immunohistochemistry and the mechanisms of lung remodeling through histopathology, employing orcein, Masson's trichrome, and periodic acid-Schiff staining. Results: Copaiba oil treatment (CO) reduced IL-33 and increased FOXP3 by stimulating the FOXP3/GATA3 and FOXP3/STAT3 pathways. Additionally, it upregulated TBET, suggesting an additional role in controlling GATA3 activity. In the respiratory epithelium, CO decreased the fragmentation of elastic fibers while increasing the deposition of collagen fibers, favoring epithelial restructuring. Simultaneously, CO reduced goblet cell hyperplasia. Discussion: Although additional research is warranted, the demonstrated anti-inflammatory and re-epithelializing action makes CO a viable option in exploring new treatments for acute allergic asthma. Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. (Copyright © 2024 Caputo, Alves, Laranjeira, Fonseca-Rodrigues, da Silva Filho, Dias, Pinto-Ribeiro, Pereira Junior, de Paula, Nagato and Corrêa.) |
References: | Sci Rep. 2020 May 26;10(1):8721. (PMID: 32457454) Front Immunol. 2017 Apr 24;8:475. (PMID: 28484466) PLoS One. 2011;6(5):e19889. (PMID: 21625544) Antioxidants (Basel). 2021 May 11;10(5):. (PMID: 34064830) Am J Respir Cell Mol Biol. 2016 Jan;54(1):41-50. (PMID: 26074138) Respir Res. 2011 Sep 21;12:122. (PMID: 21936897) Biochemistry (Mosc). 2021 Nov;86(11):1489-1501. (PMID: 34906042) J Allergy Clin Immunol. 1999 Feb;103(2 Pt 1):215-22. (PMID: 9949310) Molecules. 2019 Jun 27;24(13):. (PMID: 31252611) J Cell Commun Signal. 2018 Sep;12(3):615-624. (PMID: 29705949) Clin Sci (Lond). 2020 May 15;134(9):1063-1079. (PMID: 32369100) Asthma Res Pract. 2022 Apr 13;8(1):2. (PMID: 35418159) Matrix Biol. 2023 Dec;124:1-7. (PMID: 37922998) Rev Col Bras Cir. 2016 Dec;43(6):445-451. (PMID: 28273215) Cytokine. 2022 Aug;156:155891. (PMID: 35640416) Cells. 2019 Apr 11;8(4):. (PMID: 30979017) Eur Respir J. 2015 Dec;46(6):1796-804. (PMID: 26541520) Int Immunopharmacol. 2022 Feb;103:108487. (PMID: 34959187) Front Immunol. 2023 Feb 23;14:1128023. (PMID: 36911735) Allergy. 2023 Feb;78(2):402-417. (PMID: 36463491) Molecules. 2012 Mar 30;17(4):3866-89. (PMID: 22466849) Int Immunopharmacol. 2020 Mar;80:106177. (PMID: 32007706) Phytomedicine. 2021 Aug;89:153610. (PMID: 34175589) Front Mol Biosci. 2021 Oct 25;8:717962. (PMID: 34760922) Life Sci. 2019 Feb 15;219:40-73. (PMID: 30620895) J Ethnopharmacol. 2018 Mar 1;213:256-261. (PMID: 29158156) Pharm Biol. 2022 Dec;60(1):1520-1532. (PMID: 35952388) Clin Exp Allergy. 2005 Jul;35(7):880-3. (PMID: 16008673) J Immunol Res. 2018 Jun 14;2018:3096183. (PMID: 30013989) Int J Tuberc Lung Dis. 2022 Nov 25;26(Supp 1):1-104. (PMID: 36303302) Plants (Basel). 2023 Feb 27;12(5):. (PMID: 36903915) Immunol Lett. 2019 Mar;207:73-83. (PMID: 30659868) Exp Ther Med. 2019 Jan;17(1):3-10. (PMID: 30651758) Ann Transl Med. 2021 Jun;9(12):1015. (PMID: 34277815) Matrix Biol. 2018 Nov;73:77-104. (PMID: 29524630) Curr Opin Pulm Med. 2020 Jan;26(1):69-76. (PMID: 31408015) Clin Rev Allergy Immunol. 2022 Feb;62(1):240-263. (PMID: 34542807) J Biol Chem. 2002 Mar 29;277(13):10967-72. (PMID: 11788590) Am J Physiol Lung Cell Mol Physiol. 2014 Aug 1;307(3):L252-60. (PMID: 24879055) J Pharm Pharmacol. 2021 Sep 7;73(10):1319-1329. (PMID: 34313776) Immun Inflamm Dis. 2015 Sep;3(3):321-37. (PMID: 26417446) Pathogens. 2022 Dec 15;11(12):. (PMID: 36558881) Front Pharmacol. 2023 Sep 01;14:1215437. (PMID: 37719866) Mol Med Rep. 2021 May;23(5):. (PMID: 33760131) Front Pharmacol. 2022 Sep 16;13:851374. (PMID: 36188610) Exp Lung Res. 2019 Apr - May;45(3-4):65-75. (PMID: 31112061) Front Immunol. 2022 Jul 11;13:862866. (PMID: 35898499) Biomed Pharmacother. 2018 Jul;103:1294-1301. (PMID: 29864911) Chest. 2018 Jul;154(1):169-176. (PMID: 29170036) Front Immunol. 2022 Aug 12;13:974066. (PMID: 36032162) Br J Pharmacol. 2009 Oct;158(4):1074-87. (PMID: 19438512) Molecules. 2014 Aug 21;19(8):12814-26. (PMID: 25153880) Int J Mol Med. 2020 Aug;46(2):641-652. (PMID: 32626920) Biomedicines. 2022 Apr 28;10(5):. (PMID: 35625754) Nitric Oxide. 2021 Nov 1;116:27-34. (PMID: 34478846) Immunol Lett. 2020 Feb;218:5-10. (PMID: 31863784) Respirology. 2017 Jul;22(5):874-885. (PMID: 28401621) Acta Histochem. 2016 Jul;118(6):615-624. (PMID: 27425653) BMC Complement Altern Med. 2017 Jun 14;17(1):313. (PMID: 28615025) Clin Rev Allergy Immunol. 2019 Apr;56(2):219-233. (PMID: 30206782) Front Med (Lausanne). 2020 May 21;7:191. (PMID: 32509793) J Allergy Clin Immunol Pract. 2020 Feb;8(2):429-440. (PMID: 32037107) Annu Rev Pathol. 2023 Jan 24;18:387-409. (PMID: 36270294) Am J Respir Crit Care Med. 2019 Aug 15;200(4):431-443. (PMID: 30950644) Environ Pollut. 2019 Oct;253:507-515. (PMID: 31330343) Allergy. 2020 Aug;75(8):1918-1926. (PMID: 32124987) Int J Mol Sci. 2020 May 18;21(10):. (PMID: 32443593) Plants (Basel). 2023 Apr 11;12(8):. (PMID: 37111842) Lancet. 2018 Jan 27;391(10118):350-400. (PMID: 28911920) Biomed Pharmacother. 2017 Jul;91:257-264. (PMID: 28463791) J Allergy Clin Immunol. 2007 Aug;120(2):472-4. (PMID: 17498792) J Ethnopharmacol. 1998 Aug;62(1):73-8. (PMID: 9720615) Tob Induc Dis. 2023 Jan 27;21:13. (PMID: 36741543) PLoS One. 2017 Oct 31;12(10):e0187380. (PMID: 29088304) Biomed Pharmacother. 2023 Aug;164:114959. (PMID: 37267637) J Appl Physiol (1985). 2021 Jun 1;130(6):1635-1645. (PMID: 33792403) Toxicol Appl Pharmacol. 2003 Jan 15;186(2):90-100. (PMID: 12639500) Chest. 2016 Mar;149(3):714-20. (PMID: 26402158) Eur J Immunol. 2017 Jan;47(1):22-30. (PMID: 27910098) Iran J Basic Med Sci. 2022 Oct;25(10):1267-1274. (PMID: 36311189) Food Sci Biotechnol. 2023 Apr 4;32(11):1551-1559. (PMID: 37637840) Rev Col Bras Cir. 2019 Nov 25;46(5):e20192245. (PMID: 31778393) Mol Aspects Med. 2022 Jun;85:100995. (PMID: 34364680) J Asthma. 2014 Jun;51(5):451-8. (PMID: 24467722) Biosci Biotechnol Biochem. 2008 Oct;72(10):2555-65. (PMID: 18838817) Bioengineering (Basel). 2021 Jan 16;8(1):. (PMID: 33467161) Mediators Inflamm. 2020 Aug 19;2020:7835284. (PMID: 32922208) Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2020 Sep;12(5):e1634. (PMID: 32267622) Front Immunol. 2019 Jun 04;10:1267. (PMID: 31214200) Heliyon. 2022 Feb 19;8(2):e08993. (PMID: 35243105) Trends Immunol. 2016 May;37(5):321-333. (PMID: 27055914) Am J Physiol Lung Cell Mol Physiol. 2017 Nov 1;313(5):L763-L771. (PMID: 28775094) Respir Res. 2023 Apr 8;24(1):105. (PMID: 37031200) |
فهرسة مساهمة: | Keywords: Copaifera langsdorffii Desf; airway remodeling; anti-inflammatory agent; asthma; lung inflammation; natural products; re-epithelialization |
تواريخ الأحداث: | Date Created: 20240426 Latest Revision: 20240427 |
رمز التحديث: | 20240427 |
مُعرف محوري في PubMed: | PMC11043548 |
DOI: | 10.3389/fphar.2024.1356598 |
PMID: | 38666018 |
قاعدة البيانات: | MEDLINE |
تدمد: | 1663-9812 |
---|---|
DOI: | 10.3389/fphar.2024.1356598 |